Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Curevac N.V. (CVAC)

Curevac N.V. (CVAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 960,167
  • Shares Outstanding, K 224,338
  • Annual Sales, $ 579,120 K
  • Annual Income, $ 175,500 K
  • EBIT $ 181 M
  • EBITDA $ 201 M
  • 60-Month Beta 1.77
  • Price/Sales 1.60
  • Price/Cash Flow 4.73
  • Price/Book 0.91
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.79
  • Most Recent Earnings $-0.10 on 11/24/25
  • Next Earnings Date 04/09/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 521.07% (+6.20%)
  • Historical Volatility N/A
  • IV Percentile 96%
  • IV Rank 55.81%
  • IV High 903.83% on 11/07/25
  • IV Low 37.58% on 06/18/25
  • Expected Move (DTE 18) 1.40 (32.62%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 10
  • Volume Avg (30-Day) 70
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 1,965
  • Open Int (30-Day) 2,090
  • Expected Range 2.90 to 5.70

Most Recent Stories

More News
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode

The company reported revenue of €14.5 million for the fourth quarter, representing a decrease of €8.1 million from the corresponding period of 2023, and below an analyst estimate of €20.58, according...

BBC : 39.00 (-1.41%)
CVAC : 4.31 (+0.23%)
ONEQ : 92.15 (-0.70%)
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation

CVAC : 4.31 (+0.23%)
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid...

CVAC : 4.31 (+0.23%)
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancer

CVAC : 4.31 (+0.23%)
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form

CVAC : 4.31 (+0.23%)
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators

CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio

CVAC : 4.31 (+0.23%)
2 Small-Cap Stocks Set to Shine in a Bull Market

Small-cap growth-orientated stocks like HTCR and CVAC often outperform during bullish markets due to their sensitivity to improving economic conditions.

CVAC : 4.31 (+0.23%)
HTCR : 0.3499 (+1.07%)
IWM : 249.91 (-0.60%)
Is the Options Market Predicting a Spike in CureVac (CVAC) Stock?

Investors in CureVac N.V. CVAC need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $06.00 Call had some of the highest implied volatility...

CVAC : 4.31 (+0.23%)
Analysts Predict Strong Growth for Cancer Vaccine Market: Key Biotech Stocks to Consider

Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – Back in 2022, Nature published...

BVAXF : 0.1786 (-10.70%)
BIOV.CN : 0.2200 (-8.33%)
CVAC : 4.31 (+0.23%)
VXRT : 0.3491 (+0.90%)
IBRX : 2.06 (-3.74%)
BNTX : 94.80 (+0.30%)
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM

CVAC : 4.31 (+0.23%)
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar